Bright Green Corp. (BGXX) has released an update.
Bright Green Corporation has announced their successful acquisition of final approval from the New Mexico Board of Pharmacy and the DEA, granting them the ability to engage in research, production, and manufacturing involving Schedule I and II plant-based drugs and APIs. This pivotal development marks a significant milestone for the company, potentially impacting its position in the pharmaceutical and biotech sectors.
For further insights into BGXX stock, check out TipRanks’ Stock Analysis page.
